SWKH$16.42
Chart
Performance
Key Stats
AI SWKH Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuySWK Holdings Corporation shows strong profitability and a healthy balance sheet, with positive long-term technical indicators, though recent performance metrics and current valuation warrant careful consideration. The company operates in the healthcare sector, offering potential for growth.
Thematic
SWK Holdings operates in the healthcare and biopharma sectors, which benefit from long-term growth trends in medical innovation and an aging population. However, specific thematic tailwinds are not explicitly detailed in the provided data.
Fundamental
SWK Holdings demonstrates strong profitability with high net margins, a solid balance sheet with manageable debt levels, and positive free cash flow generation, indicating sound financial health. The P/E ratio is relatively low, suggesting potential undervaluation.
Technical
SWK Holdings' stock shows a strong upward trend on longer timeframes, with several moving averages indicating positive momentum. However, some short-term oscillators suggest a neutral to slightly overbought condition.
| Factor | Score |
|---|---|
| Healthcare Sector Growth | 70 |
| Biopharmaceutical Innovation | 65 |
| Investment Focus | 60 |
| Factor | Score |
|---|---|
| Valuation | 75 |
| Profitability | 95 |
| Growth | 80 |
| Balance Sheet Health | 90 |
| Cash Flow | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 85 |
| Momentum | 65 |
| Volume Confirmation | 70 |
| Support & Resistance | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Strong EPS Surprise
The company has shown a significant positive EPS surprise of 127.59% in Q2 2025, indicating strong earnings performance relative to analyst expectations.
Attractive P/E Ratio
The trailing P/E ratio is 10.82, which may suggest an attractive valuation compared to its historical levels or industry peers, especially considering the EPS TTM of 1.41.
Bearish Points (8)
High Quarterly P/S Ratio
The P/S ratio for Q1 2025 is 10.5, which is significantly higher than the annual P/S ratio of 2.5 for 2024, suggesting a potentially overvalued state on a quarterly basis.
Negative EPS Surprise in Q1 2025
The company reported a -42.55% EPS surprise in Q1 2025, indicating a significant miss on earnings expectations for that period.
Calendar
April 2025
24
Ex-Dividend Date
May 2025
8
Next Dividend Date
August 2025
13
Next Earnings Date
H: $0.18
A: $0.18
L: $0.18
Profile
SWK Holdings Corporation is a principal investment firm. The firm prefers to invest in healthcare, biopharma, medical devices, diagnostics, life science tools and healthcare service sectors. The firm prefers to invest between $5 million and $20 million transactions. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was incorporated in 1996 and is headquartered in Dallas, Texas.
Seasonals
Price Target
18.00 USD
The 39 analysts offering 1 year price forecasts for SWKH have a max estimate of 18.00 and a min estimate of 18.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
The largest publicly traded royalty acquisition company, a direct and major peer to SWK Holdings in the life sciences royalty market, acquiring interests in commercial and late-stage biopharmaceutical product royalties.
Weight: 90
A publicly traded biotechnology royalty aggregator that acquires economic rights to future milestone and royalty payments from pre-commercial clinical candidates, directly comparable to SWK Holdings' focus.
Weight: 88
A leading biotechnology company whose innovative drugs generate significant royalty streams, representing the core type of intellectual property and assets that SWK Holdings aims to finance or acquire royalties from.
Weight: 85
A global alternative asset manager with 'Blackstone Life Sciences,' a dedicated division actively involved in structured financings, including royalty and revenue interest deals, within the life sciences sector.